Review Queue

Claims auto-flagged for provider review (dosing, safety, contraindication, regulatory). Not patient-facing.

Priority	Type	Claim	Document
high	safety	Safety considerations.	view
high	safety	Safety and regulatory considerations.	view
high	safety	Human safety data are limited and the regulatory status varies by jurisdiction; it is not an approved drug in many regions.	view
high	safety	Safety considerations.	view
high	regulatory	Proponents describe normalization of regulatory markers and symptom improvement in selected CIRS patients.	view
high	regulatory	Vasoactive intestinal peptide (VIP) is an endogenous neuropeptide with broad regulatory roles in immune modulation, vasodilation, and neuroendocrine signaling.	view
high	safety	Safety: human data are limited and regulatory status varies; sourcing/purity are practical concerns.	view
high	regulatory	TB-500 is a synthetic fragment of Thymosin beta-4 (TB4), an actin-binding regulatory peptide.	view
high	safety	Safety: generally favorable in topical use; systemic human data are limited.	view
high	safety	Safety: human evidence limited; regulatory status varies.	view
high	regulatory	Semax is a synthetic ACTH(4-10) analog, approved and used in Russia for stroke and cognitive indications; Western evidence is limited.	view
high	safety	Safety: intranasal use; regulatory status outside Russia is investigational.	view
high	safety	Safety: intranasal; investigational outside Russia.	view
high	regulatory	Selank is a synthetic analog of the immunomodulatory peptide tuftsin, approved in Russia for anxiety; Western evidence is limited.	view
high	safety	Safety: Western peer-reviewed evidence is limited.	view
high	safety	Safety: relatively well tolerated where approved; status varies by jurisdiction.	view
high	regulatory	Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog, FDA-approved for HIV-associated lipodystrophy.	view
high	safety	Safety: human evidence limited; not an approved drug in many regions; glucose/IGF-1 monitoring considerations.	view
high	safety	Safety: human evidence limited; regulatory status varies.	view
high	safety	Safety: human data limited.	view
high	safety	Safety: investigational.	view
high	safety	Safety: human evidence limited.	view
high	safety	Safety: human efficacy evidence is limited.	view
high	safety	Safety: preclinical only; no established human data.	view
high	safety	High reactivity is a key safety consideration before introducing new agents.	view
high	regulatory	Materials and Methods Ethical Statement Approved by the Institutional Animal Care and Use Committee (IACUC) under protocol #2026-MUR-056, complying with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and EU Directive 2010/63/EU.	view
high	safety	GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Introduction Epstein-Barr virus (EBV) is a gammaherpesvirus that establishes lifelong latency, causing persistent inflammation, oxidative stress, mitochondrial dysfunction, and immune dysregulation, often leading to chronic symptoms and increased risk of autoimmune and oncologic complications.	view
high	safety	No adverse effects were observed.	view
high	safety	Safety Mild reactions possible (injection sites).	view
high	safety	GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Results Survival 100%; no toxicity.	view
high	safety	Safety Mild reactions possible (injection sites).	view
high	safety	Results Survival 100%; no toxicity.	view
high	regulatory	GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Materials and Methods Ethical Statement Approved by the Institutional Animal Care and Use Committee (IACUC) under protocol #2026-MUR-061, complying with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and EU Directive 2010/63/EU.	view
high	safety	No adverse effects were observed.	view
high	safety	Goal: Zero symptoms, negative tests within 6 months Safety Mild reactions possible (injection sites).	view
high	safety	Results Survival 100%; no toxicity.	view
high	regulatory	Approved by the Institutional Animal Care and Use Committee (IACUC) under protocol #2026-MUR-038, complying with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and EU Directive 2010/63/EU.	view
high	safety	No adverse effects were observed.	view
high	safety	No adverse effects were observed.	view
high	safety	Safety Mild reactions possible (injection sites).	view
high	safety	GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Results Survival 100%; no toxicity.	view
high	regulatory	Materials and Methods Ethical Statement Approved by the Institutional Animal Care and Use Committee (IACUC) under protocol #2026-MUR-056, complying with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and EU Directive 2010/63/EU.	view
high	safety	GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Introduction Epstein-Barr virus (EBV) is a gammaherpesvirus that establishes lifelong latency, causing persistent inflammation, oxidative stress, mitochondrial dysfunction, and immune dysregulation, often leading to chronic symptoms and increased risk of autoimmune and oncologic complications.	view
high	safety	Risk of injection-site irritation.	view
high	safety	KPV is generally well tolerated; avoid in pregnancy and lactation due to insufficient safety data.	view
urgent	dosing	This summary is mechanistic background for provider review and is not a treatment recommendation or dosing guidance.	view
urgent	dosing	This summary organizes mechanistic and preclinical background for provider review and does not constitute a treatment recommendation or dosing guidance.	view
urgent	dosing	This is expert-opinion-level background organized for provider review, not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	contraindication	Safety: contraindicated in active malignancy and pregnancy; monitor glucose/IGF-1 — these are physician-managed considerations.	view
urgent	dosing	Background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	This overview and the per-bioregulator notes are organizational background for provider review only — not treatment recommendations or dosing guidance.	view
urgent	dosing	Organizational background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Organizational background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Organizational background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Organizational background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Organizational background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Organizational background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Organizational background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Organizational background for provider review only — not a treatment recommendation or dosing guidance.	view
urgent	dosing	Selenium: 200 mcg daily orally (8 AM).	view
urgent	dosing	DGL: 400 mg before meals orally.	view
urgent	dosing	This study evaluates the combined administration of Monolaurin (1000 mg three times a day orally with food), Thymosin Alpha-1 (1 mg three times a week subcutaneously), KPV (400 mcg twice per day subcutaneously), SS-31 (1 mg daily subcutaneously), MOTS-c (1 mg daily subcutaneously), Zinc (30 mg daily orally), Vitamin D3 (10,000 IU daily orally), B12 (full daily oral dose), Folate (full daily oral dose), Selenium (200 mcg daily orally), Magnesium Glycinate (400 mg daily orally), and DGL (400 mg before meals orally) on Epstein-Barr virus (EBV) reversal in a murine gammaherpesvirus 68 (MHV-68) model in adult male C57BL/6 mice over a 12-week period.	view
urgent	dosing	GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Compound Administration Compounds (>98% purity, certified suppliers) administered using exact specified dosages without alteration: Monolaurin: 1000 mg three times a day orally with food (scaled gavage).	view
urgent	dosing	Thymosin Alpha-1: 1 mg three times a week subcutaneously (Mon/Wed/Fri, 8 AM).	view
urgent	dosing	KPV: 400 mcg twice per day subcutaneously (8 AM/PM).	view
urgent	dosing	SS-31: 1 mg daily subcutaneously (8 AM).	view
urgent	dosing	MOTS-c: 1 mg daily subcutaneously (8 AM).	view
urgent	dosing	Zinc: 30 mg daily orally (8 AM).	view
urgent	dosing	Vitamin D3: 10,000 IU daily orally (8 AM).	view
urgent	dosing	B12: full daily oral dose (8 AM).	view
urgent	dosing	Folate: full daily oral dose (8 AM).	view
urgent	dosing	Magnesium Glycinate: 400 mg daily orally (evening).	view
urgent	dosing	This study evaluates the combined administration of BPC-157 (500 mcg subcutaneously twice daily), KPV (500 mcg subcutaneously twice daily), Thymosin Alpha-1 (1.5 mg subcutaneously three times weekly), GHK-Cu (2 mg subcutaneously daily), Benfotiamine (B1, 500 mg daily orally), Methylcobalamin (B12, 500 mcg three times daily orally), Zinc (30 mg daily orally), Vitamin D3 (5,000 IU daily orally), Vitamin K2 (200 mcg daily orally), and Folate (500 mcg daily orally) on Bell’s palsy reversal in a facial nerve crush injury model in adult male C57BL/6 mice over a 12-week period.	view
urgent	dosing	Compound Administration Compounds (>98% purity, certified suppliers) administered using exact specified dosages without alteration: BPC-157: 500 mcg subcutaneously twice daily (8 AM/PM).	view
urgent	dosing	Methylcobalamin (B12): 500 mcg three times daily orally (8 AM/PM).	view
urgent	dosing	Benfotiamine (B1): 500 mg daily orally (8 AM).	view
urgent	dosing	GHK-Cu: 2 mg subcutaneously daily (8 AM).	view
urgent	dosing	Zinc: 30 mg daily orally (8 AM).	view
urgent	dosing	Vitamin D3: 5,000 IU daily orally (8 AM).	view
urgent	dosing	Vitamin K2: 200 mcg daily orally (8 AM).	view
urgent	dosing	Folate: 500 mcg daily orally (8 AM).	view
urgent	dosing	Thymosin Alpha-1: 1.5 mg subcutaneously three times weekly (Mon/Wed/Fri, 8 AM).	view
urgent	dosing	KPV: 500 mcg subcutaneously twice daily (8 AM/PM).	view
urgent	dosing	Glutathione: 500 mg three times a week subcutaneously (e.g., Mon/Wed/Fri, 8 AM)	view
urgent	dosing	This study evaluates the combined administration of Thymosin Alpha-1 (1.5 mg three times a week subcutaneously), BPC-157 (1 mg daily subcutaneously), TB-500 (5 mg every five days subcutaneously), LL-37 (200 mcg daily subcutaneously), MOTS-c (3 mg three times a week subcutaneously), SS-31 (2 mg daily subcutaneously), CJC-1295 with DAC (1 mg per week subcutaneously), Ipamorelin (250 mcg nightly subcutaneously), and Nicotine (7 mg daily transdermal patch) on Lyme disease reversal in Borrelia burgdorferi-infected adult male C57BL/6 mice over a 12-week period.	view
urgent	dosing	Lyme disease induced by subcutaneous Borrelia burgdorferi (strain B31, 10^5 spirochetes).	view
urgent	dosing	GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Compound Administration Compounds (>98% purity, Elitebiogenix) Thymosin Alpha-1: 1.5 mg three times a week subcutaneously (e.g., Mon/Wed/Fri, 8 AM).	view
urgent	dosing	BPC-157: 1 mg daily subcutaneously (8 AM).	view
urgent	dosing	TB-500: 5 mg every five days subcutaneously (8 AM).	view
urgent	dosing	LL-37: 200 mcg daily subcutaneously (8 AM).	view
urgent	dosing	MOTS-c: 3 mg three times a week subcutaneously (e.g., Mon/Wed/Fri, 8 AM).	view
urgent	dosing	SS-31: 2 mg daily subcutaneously (8 AM).	view
urgent	dosing	CJC-1295 with DAC: 1 mg per week subcutaneously (Mondays, 8 AM).	view
urgent	dosing	Ipamorelin: 250 mcg nightly subcutaneously (8 PM).	view
urgent	dosing	Nicotine: 7 mg daily transdermal patch (applied 8 AM, changed every 24 hours).	view
urgent	dosing	Glutathione: 500 mg three times a week subcutaneously (e.g., Mon/Wed/Fri, 8 AM) Nutrient Protocol Magnesium Bisglycinate: 600 mg daily (PM0 Zinc: 30 mg daily Methylated B Complex D3: 5000 IU (taken with K2) daily K2: 200 mcg (taken with D3) daily Ubiquinol: 200 mg daily Treatment lasted 6 months Outcome Measures Bacterial Clearance: qPCR for Borrelia DNA in joints, heart, bladder at endpoint.	view
urgent	dosing	Daily/Weekly Schedule Nicotine: 7 mg patch daily (apply morning, change daily; rotate sites).	view
urgent	dosing	BPC-157: 1 mg s.c.	view
urgent	dosing	TB-500: 5 mg s.c.	view
urgent	dosing	LL-37: 200 mcg s.c.	view
urgent	dosing	MOTS-c: 3 mg s.c.	view
urgent	dosing	SS-31: 2 mg s.c.	view
urgent	dosing	CJC-1295 with DAC: 1 mg s.c.	view
urgent	dosing	Ipamorelin: 250 mcg s.c.	view
urgent	dosing	Thymosin Alpha-1: 1.5 mg s.c.	view
urgent	dosing	Nutrient Protocol Magnesium Bisglycinate: 600 mg daily (PM0 Zinc: 30 mg daily Methylated B Complex D3: 5000 IU (taken with K2) daily K2: 200 mcg (taken with D3) daily Ubiquinol: 200 mg daily GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Monitoring Daily: Symptom diary (pain/fatigue 0-10).	view
urgent	dosing	Vitamin D3: 10,000 IU daily orally (8 AM).	view
urgent	dosing	B12: full daily oral dose (8 AM).	view
urgent	dosing	GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Compound Administration Compounds (>98% purity, certified suppliers) administered using exact specified dosages without alteration: Monolaurin: 1000 mg three times a day orally with food (scaled gavage).	view
urgent	dosing	Folate: full daily oral dose (8 AM).	view
urgent	dosing	Selenium: 200 mcg daily orally (8 AM).	view
urgent	dosing	Magnesium Glycinate: 400 mg daily orally (evening).	view
urgent	dosing	DGL: 400 mg before meals orally.	view
urgent	dosing	KPV: 400 mcg twice per day subcutaneously (8 AM/PM).	view
urgent	dosing	This study evaluates the combined administration of Monolaurin (1000 mg three times a day orally with food), Thymosin Alpha-1 (1 mg three times a week subcutaneously), KPV (400 mcg twice per day subcutaneously), SS-31 (1 mg daily subcutaneously), MOTS-c (1 mg daily subcutaneously), Zinc (30 mg daily orally), Vitamin D3 (10,000 IU daily orally), B12 (full daily oral dose), Folate (full daily oral dose), Selenium (200 mcg daily orally), Magnesium Glycinate (400 mg daily orally), and DGL (400 mg before meals orally) on Epstein-Barr virus (EBV) reversal in a murine gammaherpesvirus 68 (MHV-68) model in adult male C57BL/6 mice over a 12-week period.	view
urgent	dosing	Thymosin Alpha-1: 1 mg three times a week subcutaneously (Mon/Wed/Fri, 8 AM).	view
urgent	dosing	SS-31: 1 mg daily subcutaneously (8 AM).	view
urgent	dosing	MOTS-c: 1 mg daily subcutaneously (8 AM).	view
urgent	dosing	Zinc: 30 mg daily orally (8 AM).	view
urgent	dosing	LL-37 50 mcg subcutaneous every other day; LL-37 has antimicrobial and immunomodulatory properties and may cause injection-site inflammation.	view
urgent	dosing	BPC-157 250 mcg subcutaneous twice daily for 4 weeks, then 250 mcg once daily for maintenance.	view
urgent	dosing	TB-500 / TB4 2 mg subcutaneous twice weekly for 6 weeks.	view
urgent	contraindication	These agents may cause transient injection-site reactions and lightheadedness; they are contraindicated in patients with active malignancy.	view
urgent	dosing	KPV 500 mcg subcutaneous daily, or 500 mcg orally twice daily for gut-directed support, for 8 weeks.	view
urgent	dosing	CJC-1295 100 mcg subcutaneous nightly at bedtime, five nights on and two nights off, for 12 weeks.	view
urgent	dosing	Ipamorelin 200 mcg subcutaneous nightly.	view
urgent	contraindication	This combination may cause water retention, flushing, and tingling; use caution in patients with insulin resistance and contraindicated in active cancer.	view
urgent	dosing	MOTS-c 10 mg subcutaneous three times weekly for 4 weeks.	view
urgent	dosing	SS-31 (elamipretide) dosing per provider judgment.	view
urgent	dosing	GHK-Cu 2 mg subcutaneous daily for 30 days for skin and connective tissue.	view